CSH Medical Equipment (Shanghai) Co., Ltd (“CSH Medical”) recently has announced the completion of nearly one hundred million CNY in Series A+ funding.
CSH Medical is an innovative enterprise specializing in the research and development, production, and sales of biomagnet medical imaging equipment. The products include unshielded multi-channel MCG (magnetocardiography) and committed to exploring the biomedical market for biomagnet medical imaging, achieving early monitoring of human heart and brain health, and meeting the needs of medical service providers and patients.
According to CSH Medical, it takes magnetocardiogram technology as the entry point, accelerates the research and development of biomagnetic technology and clinical research, and comprehensively lays out biomagnetic imaging diagnostic equipment. Its core product is a highly sensitive magnetocardiogram. The sensitivity reaches 5 femtoseconds, and through the development of AI intelligent analysis models, the accuracy of magnetocardiogram analysis and diagnosis reaches 87.8%.
According to Frost & Sullivan, the global market size of medical image equipment was USD 70.4 billion in 2021, it is predicted to reach USD 84.3 billion in 2026, with a compound annual growth rate of 3.7%. This growth is driven by the improvement of residents' ability to pay, progress in medical imaging technology, and continuous growth in demand for imaging equipments.
In addition to CSH Medical, many companies are competing in the medical image equipment market, such as Mindray (迈瑞医疗), United Imaging (联影医疗), Neusoft Medical (东软医疗), Minfound (明峰医疗), Wandong Medical (万东医疗) in China, Siemens in Germany, GE in the United States, Hitachi in Japan and Philips in the Netherland.
Shulin Zhang, general manager of CSH Medical, stated: "CSH Medical will take magnetocardiogram as the starting point, create a high-end biomedical imaging technology research and transformation platform, promote deep integration of industry, academia, research and medicine, collaborative innovation, accelerate the development and market expansion of biomedical imaging products, comprehensively layout the fields of magnetic imaging, magnetic detection, and magnetic therapy, to achieve high-level development of China's independent magnetic medical equipment.”
This round of financing for CSH Medical was exclusively invested by Xinding Capital (新鼎资本). This round of funds will mainly be used for the research and development iteration of magnetocardiogram technology, conducting large-scale MCG clinical research and promoting the establishment of domestic clinical standards for magnetocardiogram, as well as the clinical trial registration of fetal magnetocardiogram (fMCG) for early congenital heart disease examination.